Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

The article focuses on a study which evaluated the effectiveness and safety of the addition of bortezomib to thalidomide plus dexamethasone (TD) (VTD) against TD alone as induction therapy prior to double analogous stem-cell transplantation in multiple myeloma. Patients at the Grupo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Myeloma Network hospitals were selected. Results indicate that patients eligible for transplant, induction and consolidation therapy with VTD improved clinical outcomes compared to patients receiving only TD therapy.